Analytical Data
-
Gene name
Coagulation Factor XIV/PROC
- Application
-
Alternative Names
P5C reductase；P5CR；PCA reductase
-
Species
Mycobacterium tuberculosis
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P9WHU7
-
Expression Region
1-295aa
-
Molecular Weight
37.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Coagulation Factor XIV, also known as Protein C (PROC), plays a crucial role in the regulation of blood coagulation and the inflammatory response. It is produced in the liver and is activated to activated Protein C (APC) by thrombin in the presence of thrombomodulin. The activated Protein C serves as an anticoagulant, limiting clot formation and facilitating fibrinolysis, thus maintaining hemostatic balance. Research into recombinant PROC focuses on its therapeutic potential in treating various clotting disorders and thromboembolic diseases, particularly in patients with Protein C deficiency or severe coagulopathies. Given the complexities associated with traditional therapeutic agents—such as their limited efficacy, risk of bleeding complications, and challenging dosing protocols—advancements in recombinant technologies hold promise for the development of safer and more effective treatments. Recent studies emphasize the importance of optimizing recombinant PROC production systems to achieve high yields and proper post-translational modifications. Continued investigation into the pharmacodynamics and clinical applications of recombinant PROC aims to enhance our understanding of its anticoagulant mechanisms while overcoming the limitations of existing therapies, potentially leading to improved outcomes for individuals affected by coagulation abnormalities.
